Abstract
A structure-activity relationship (SAR) dataset was generated for a set of acetylcholinesterase inhibitors using Adaboost and physicochemical parameters. After calculation, it is found that the ACC of SAR model is 99.51 by using 10-fold cross-validation test, while 99.35% for independent test set. Based on the SAR prediction model, bakuchiol is predicted to be an acetylcholinesterase inhibitor. Fluorescence was used to investigate the binding between bakuchiol and acetylcholinesterase, which can provide valuable qualitative and quantitative information about the interaction between acetylcholinesterase and bakuchiol.
Keywords: Molecular descriptors, acetylcholinesterase, bakuchiol, Adaboost.
Graphical Abstract
Current Bioinformatics
Title:Prediction of an Interaction between Bakuchiol and Acetylcholinesterase using Adaboost
Volume: 11 Issue: 1
Author(s): Can Zhang, Xueyuan Wang, Lei Gu, Li Jiang, Qiang Su, Manman Zhao, Linfeng Zheng, Ling Tang, Fuxue Chen and Bing Niu
Affiliation:
Keywords: Molecular descriptors, acetylcholinesterase, bakuchiol, Adaboost.
Abstract: A structure-activity relationship (SAR) dataset was generated for a set of acetylcholinesterase inhibitors using Adaboost and physicochemical parameters. After calculation, it is found that the ACC of SAR model is 99.51 by using 10-fold cross-validation test, while 99.35% for independent test set. Based on the SAR prediction model, bakuchiol is predicted to be an acetylcholinesterase inhibitor. Fluorescence was used to investigate the binding between bakuchiol and acetylcholinesterase, which can provide valuable qualitative and quantitative information about the interaction between acetylcholinesterase and bakuchiol.
Export Options
About this article
Cite this article as:
Zhang Can, Wang Xueyuan, Gu Lei, Jiang Li, Su Qiang, Zhao Manman, Zheng Linfeng, Tang Ling, Chen Fuxue and Niu Bing, Prediction of an Interaction between Bakuchiol and Acetylcholinesterase using Adaboost, Current Bioinformatics 2016; 11 (1) . https://dx.doi.org/10.2174/1574893611666151119220248
DOI https://dx.doi.org/10.2174/1574893611666151119220248 |
Print ISSN 1574-8936 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-392X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cerebroprotective Functions of HO-2
Current Pharmaceutical Design The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry ERRATUM 2
Current Neuropharmacology The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews Do we Need a New Procedure for the Assessment of Adverse Events in Anti-migraine Clinical Trials?
Recent Patents on CNS Drug Discovery (Discontinued) Editorial:Metabolic, Pathological, and Therapeutic Perspectives Intracellular 5’-Nucleotidases.
Current Medicinal Chemistry Meet the Editorial Board Member
CNS & Neurological Disorders - Drug Targets Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Role of Noradrenergic and Orexinergic Neurons in General Anesthesia
Current Neuropharmacology ISATIN: New Hope Against Convulsion
Central Nervous System Agents in Medicinal Chemistry Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Array-Comparative Genomic Hybridization Analysis of a Cohort of Saudi Patients with Epilepsy
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry Therapeutic Potential of Neurogenesis for Prevention and Recovery from Alzheimers Disease: Allopregnanolone as a Proof of Concept Neurogenic Agent
Current Alzheimer Research Principles and Applications of Diffuse Optical Imaging for the Brain
Current Medical Imaging Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Early Life Stress in Depressive Patients: Role of Glucocorticoid and Mineralocorticoid Receptors and of Hypothalamic-Pituitary-Adrenal Axis Activity
Current Pharmaceutical Design Evaluation of Vancoplus Versus Ceftriaxone Against Cephalosporin Resistance MRSA Strain in Experimental Meningitis Model
Cardiovascular & Hematological Disorders-Drug Targets